Yanqun Dong1, Karen J. Ruth2, Thomas M. Churilla1, Rosalia Viterbo3, Mark L. Sobczak1, Marc C. Smaldone3, David Y.T. Chen3, Robert G. Uzzo3, Mark H. Hallman1, Eric M. Horwitz1
Canadian Journal of Urology, Vol.24, No.1, pp. 8656-8662, 2017
Abstract Introduction: To evaluate if androgen deprivation therapy (ADT) improves outcomes for patients with localized, intermediate-risk prostate cancer treated with definitive external beam radiation therapy (EBRT) in the dose-escalated era.
Materials and methods: This is a retrospective study using a single institutional database. We included patients with localized, intermediate-risk prostate cancer treated with dose-escalated radiation therapy (RT) with 3D conformal radiotherapy or intensity-modulated radiotherapy (74-80 Gy in daily fraction of 1.8 Gy-2.0 Gy, or 70.2 Gy in daily fraction of 2.7 Gy) from 1992 to 2013. To further risk stratify the patients, PSA 10 ng/mL-20 ng/mL, Gleason 3+4,… More >